On November 11, Gelonhui reported that Sino Biopharm (01177.HK) announced that the jointly developed KRAS G12C inhibitor Garsorasib tablets 'Garsorasib' (trade name: Anfaining) has received market approval from the China National Medical Products Administration for the treatment of advanced non-small cell lung cancer (NSCLC) adult patients with at least one prior systemic treatment of KRAS G12C mutant.
中国生物制药(01177.HK)：KRAS G12C抑制剂格索雷塞片“GARSORASIB”获批上市
sino biopharm (01177.HK): KRAS G12C inhibitor Sotorasib tablets "GARSORASIB" approved for marketing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated